

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6715441

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BRENDAN MARK JOHNSON	10/27/2017
PAUL N. MUDD JR.	10/26/2017
SUSAN WOLLOWITZ	10/27/2017
RECEIVING PARTY DATA	
Name:	ROIVANT SCIENCES, INC.
Street Address:	320 WEST 37TH STREET
Internal Address:	5TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10018
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17317769
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 843-5306
Email:	zIPPatentDocketingMailboxUS@cooley.com, pellison@cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	ATTN: IP DOCKETING DEPARTMENT, MATTHEW C. STEVENS
Address Line 2:	1299 PENNSYLVANIA AVENUE NW, SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	MYOV-014/03US 329454-2747
NAME OF SUBMITTER:	MATTHEW C. STEVENS
SIGNATURE:	/Matthew C. Stevens/
DATE SIGNED:	05/18/2021
Total Attachments: 12	
source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page1.tif	

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page2.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page3.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page4.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page5.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page6.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page7.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page8.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page9.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page10.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page11.tif

source=(6) Copy of Executed Assignment from JOHNSON, MUDD, &WOLLOWITZ to Roivant Sciences, Inc. in counterpart#page12.tif

ASSIGNMENT

Brendan Mark JOHNSON, residing at 2017 Markham Drive, Chapel Hill, North Carolina 27514, UNITED STATES OF AMERICA, Paul N. MUDD, Jr., residing at 302 Beacon Falls Court, Cary, North Carolina 27519, UNITED STATES OF AMERICA and Susan WOLLOWITZ, residing at 32 Topper Court, Lafayette, California 94549 (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled **METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS**, and which is a:

Country	Application No.	Application Date
Argentina	20170102712	September 29, 2017
International Application (PCT)	PCT/EP2017/074907	September 29, 2017

WHEREAS, Roivant Sciences, Inc., a corporation of Delaware having its principal place of business at 320 West 37th Street, 5th Floor, New York, New York 10018, UNITED STATES OF AMERICA, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).


The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.


The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 10/27/2017 By: 
Brendan Mark JOHNSON

WITNESSED BY: 
DATE: 10-27-17
NAME: Jennifer R. King

Date: _____ By: _____
Paul N. MUDD, Jr.


WITNESSED BY: _____
DATE: _____
NAME: _____


Date: _____ By: _____
Susan WOLLOWITZ

WITNESSED BY: _____
DATE: _____
NAME: _____

For and on behalf of ASSIGNEE:

Date: 11/2/17

By: 
Name: Matthew Gline
Title: Chief Financial Officer
Company: Roivant Sciences, Inc.

WITNESSED BY: 
DATE: 11/2/17
NAME: Karen Nichols

ASSIGNMENT

Brendan Mark JOHNSON, residing at 2017 Markham Drive, Chapel Hill, North Carolina 27514, UNITED STATES OF AMERICA, Paul N. MUDD, Jr., residing at 302 Beacon Falls Court, Cary, North Carolina 27519, UNITED STATES OF AMERICA and Susan WOLLOWITZ, residing at 32 Topper Court, Lafayette, California 94549 (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled **METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS**, and which is a:

Country	Application No.	Application Date
Argentina	20170102712	September 29, 2017
International Application (PCT)	PCT/EP2017/074907	September 29, 2017

WHEREAS, Roivant Sciences, Inc., a corporation of Delaware having its principal place of business at 320 West 37th Street, 5th Floor, New York, New York 10018, UNITED STATES OF AMERICA, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.


The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: _____ By: _____
Brendan Mark JOHNSON

WITNESSED BY: _____
DATE: _____
NAME: _____

Date: 10/26/17 By: 
Paul N. MUDD, Jr.


WITNESSED BY: Michelle Patterson
DATE: 10/26/2017
NAME: Michelle Patterson


Date: _____ By: _____
Susan WOLLOWITZ

WITNESSED BY: _____
DATE: _____
NAME: _____

For and on behalf of ASSIGNEE:

Date: 11/2/17

By: 
Name: Matthew Gline
Title: Chief Financial Officer
Company: Roivant Sciences, Inc.

WITNESSED BY: 
DATE: 11/2/17
NAME: Karen Nichols

ASSIGNMENT

Brendan Mark JOHNSON, residing at 2017 Markham Drive, Chapel Hill, North Carolina 27514, UNITED STATES OF AMERICA, Paul N. MUDD, Jr., residing at 302 Beacon Falls Court, Cary, North Carolina 27519, UNITED STATES OF AMERICA and Susan WOLLOWITZ, residing at 32 Topper Court, Lafayette, California 94549 (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled **METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS**, and which is a:

Country	Application No.	Application Date
Argentina	20170102712	September 29, 2017
International Application (PCT)	PCT/EP2017/074907	September 29, 2017

WHEREAS, Roivant Sciences, Inc., a corporation of Delaware having its principal place of business at 320 West 37th Street, 5th Floor, New York, New York 10018, UNITED STATES OF AMERICA, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.


Date: _____ By: _____
Brendan Mark JOHNSON

WITNESSED BY: _____
DATE: _____
NAME: _____

Date: _____ By: _____
Paul N. MUDD, Jr.


WITNESSED BY: _____
DATE: _____
NAME: _____


Date: 27-Oct-2017 By: 
Susan WOLLOWITZ

WITNESSED BY: 
DATE: 10-27-17
NAME: NATHAN N. JAESE

For and on behalf of ASSIGNEE:

Date: 11/2/17

By: 
Name: Matthew Gline
Title: Chief Financial Officer
Company: Roivant Sciences, Inc.

WITNESSED BY: 
DATE: 11/2/17
NAME: Karen Nichols